# A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants

> **NCT01762839** · PHASE1 · COMPLETED · sponsor: **Melinta Therapeutics, Inc.** · enrollment: 150 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Single-Dose IV Oritavancin Diphosphate
- **DRUG:** Placebo
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT01762839
- **Lead sponsor:** Melinta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-27
- **Primary completion:** 2013-01
- **Final completion:** 2013-02-11
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01762839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01762839, "A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT01762839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*